Characterization of a novel mutation V136L in bone morphogenetic protein 15 identified in a woman affected by POI.


Journal

Journal of ovarian research
ISSN: 1757-2215
Titre abrégé: J Ovarian Res
Pays: England
ID NLM: 101474849

Informations de publication

Date de publication:
29 Jun 2021
Historique:
received: 15 03 2021
accepted: 12 06 2021
entrez: 30 6 2021
pubmed: 1 7 2021
medline: 11 1 2022
Statut: epublish

Résumé

Premature ovarian insufficiency (POI) is an ovarian defect characterized by primary or secondary amenorrhea, hypergonadotropism and hypoestrogenism which occurs before the age of 40 years with a major genetic component. In this study we performed clinical evaluation and genetic analysis of a group of 18 patients with POI. The study involved 18 consecutive women with POI. Karyotiping and genetic analysis for research of mutations in GDF9 (Growth Differentation Factor 9) and BMP15 (Bone morphogentic protein 15) genes and FMR1 (Fragile X Mental Retardation 1) premutation were carried out. In vitro functional study of the novel BMP15 mutation was performed using COV434 (Human ovarian granulosa tumour cells 434) cells of ovarian granulosa, which consistently express BMP responsive element, and luciferase reporter assay. Three patients (17%) had a family history of POI. Ten patients (56%) had a family history of autoimmune diseases and nine patients (50%) showed a personal history of one or more autoimmune diseases. Of patients for whom morphological assessment was available, almost half (44%) had poor follicle assets or small ovaries's size at pelvic US. Two patients (13%) showed reduced bone density at DEXA (Dual Energy X-ray Absorptiometry). All the women had normal female kariotype and no mutations in the GDF-9 gene or FMR1 premutations were found. A novel heterozygous mutation c.406G > C (V136L) of BMP15 gene was identified in one patient. After transfection in COV434 cells, BMP15 variant showed a significantly reduced luciferase activity compared to wild type. POI is a multifactorial disease with several health implications. Autoimmunity and genetics represent the most common aetiology. We identified and characterized a novel BMP15 mutation, providing an additional elucidation of molecular basis of this complex disorder.

Sections du résumé

BACKGROUND BACKGROUND
Premature ovarian insufficiency (POI) is an ovarian defect characterized by primary or secondary amenorrhea, hypergonadotropism and hypoestrogenism which occurs before the age of 40 years with a major genetic component. In this study we performed clinical evaluation and genetic analysis of a group of 18 patients with POI. The study involved 18 consecutive women with POI. Karyotiping and genetic analysis for research of mutations in GDF9 (Growth Differentation Factor 9) and BMP15 (Bone morphogentic protein 15) genes and FMR1 (Fragile X Mental Retardation 1) premutation were carried out. In vitro functional study of the novel BMP15 mutation was performed using COV434 (Human ovarian granulosa tumour cells 434) cells of ovarian granulosa, which consistently express BMP responsive element, and luciferase reporter assay.
RESULTS RESULTS
Three patients (17%) had a family history of POI. Ten patients (56%) had a family history of autoimmune diseases and nine patients (50%) showed a personal history of one or more autoimmune diseases. Of patients for whom morphological assessment was available, almost half (44%) had poor follicle assets or small ovaries's size at pelvic US. Two patients (13%) showed reduced bone density at DEXA (Dual Energy X-ray Absorptiometry). All the women had normal female kariotype and no mutations in the GDF-9 gene or FMR1 premutations were found. A novel heterozygous mutation c.406G > C (V136L) of BMP15 gene was identified in one patient. After transfection in COV434 cells, BMP15 variant showed a significantly reduced luciferase activity compared to wild type.
CONCLUSIONS CONCLUSIONS
POI is a multifactorial disease with several health implications. Autoimmunity and genetics represent the most common aetiology. We identified and characterized a novel BMP15 mutation, providing an additional elucidation of molecular basis of this complex disorder.

Identifiants

pubmed: 34187539
doi: 10.1186/s13048-021-00836-7
pii: 10.1186/s13048-021-00836-7
pmc: PMC8244212
doi:

Substances chimiques

BMP15 protein, human 0
Bone Morphogenetic Protein 15 0
Hormones 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

85

Références

Genomics. 2016 Dec;108(5-6):209-215
pubmed: 27989800
Hum Reprod Update. 2015 Nov-Dec;21(6):787-808
pubmed: 26243799
J Endocrinol Invest. 2016 Sep;39(9):983-90
pubmed: 27091671
Fertil Steril. 2005 Oct;84(4):958-65
pubmed: 16213850
Am J Hum Genet. 2004 Jul;75(1):106-11
pubmed: 15136966
Maturitas. 2013 Jan;74(1):61-7
pubmed: 23107817
Annu Rev Genomics Hum Genet. 2006;7:61-80
pubmed: 16824020
Endocr Rev. 1997 Feb;18(1):107-34
pubmed: 9034788
J Clin Endocrinol Metab. 2006 May;91(5):1976-9
pubmed: 16464940
Nat Protoc. 2009;4(7):1073-81
pubmed: 19561590
PLoS One. 2013 Oct 16;8(10):e78199
pubmed: 24147118
Hum Reprod. 2016 May;31(5):926-37
pubmed: 27008889
J Clin Endocrinol Metab. 2019 Aug 1;104(8):3049-3067
pubmed: 31042289
J Autoimmun. 2009 Aug;33(1):35-41
pubmed: 19346101
Fertil Steril. 1995 Oct;64(4):740-5
pubmed: 7672145
J Biol Chem. 2000 Dec 15;275(50):39523-8
pubmed: 10998422
Hum Genet. 2006 May;119(4):408-15
pubmed: 16508750
Lancet. 2010 Sep 11;376(9744):911-21
pubmed: 20708256
J Clin Endocrinol Metab. 2016 Sep;101(9):3306-15
pubmed: 27300572
J Endocr Soc. 2017 Feb 07;1(3):162-173
pubmed: 29367954
Eur J Endocrinol. 2006 May;154(5):739-44
pubmed: 16645022
J Biol Chem. 2002 Feb 15;277(7):4883-91
pubmed: 11729207
Obstet Gynecol. 1986 Apr;67(4):604-6
pubmed: 3960433
Nat Methods. 2010 Apr;7(4):248-9
pubmed: 20354512
Clin Genet. 2017 Aug;92(2):208-212
pubmed: 28094433
Mol Cell Endocrinol. 2005 Apr 29;234(1-2):67-73
pubmed: 15836954
Hum Mutat. 2009 May;30(5):804-10
pubmed: 19263482
Trends Endocrinol Metab. 2004 Oct;15(8):356-61
pubmed: 15380806
Horm Res. 2007;68(4):196-202
pubmed: 17495481

Auteurs

Eleonora Ferrarini (E)

Dipartimento Medicina Clinica E Sperimentale, Sezione Di Endocrinologia, Università Di Pisa, Via Paradisa 2, 56124, Pisa, Italy.

Giuseppina De Marco (G)

Dipartimento Medicina Clinica E Sperimentale, Sezione Di Endocrinologia, Università Di Pisa, Via Paradisa 2, 56124, Pisa, Italy.

Francesca Orsolini (F)

Dipartimento Medicina Clinica E Sperimentale, Sezione Di Endocrinologia, Università Di Pisa, Via Paradisa 2, 56124, Pisa, Italy.

Elena Gianetti (E)

Dipartimento Medicina Clinica E Sperimentale, Sezione Di Endocrinologia, Università Di Pisa, Via Paradisa 2, 56124, Pisa, Italy.

Elena Benelli (E)

Dipartimento Medicina Clinica E Sperimentale, Sezione Di Endocrinologia, Università Di Pisa, Via Paradisa 2, 56124, Pisa, Italy.

Franca Fruzzetti (F)

Department of Obstetrics and Gynecology, University Hospital Pisa, Pisa, Italy.

Tommaso Simoncini (T)

Department of Obstetrics and Gynecology, University Hospital Pisa, Pisa, Italy.

Patrizia Agretti (P)

Laboratory of Chemistry and Endocrinology, University Hospital of Pisa, Pisa, Italy.

Massimo Tonacchera (M)

Dipartimento Medicina Clinica E Sperimentale, Sezione Di Endocrinologia, Università Di Pisa, Via Paradisa 2, 56124, Pisa, Italy. mtonacchera@hotmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH